Search this site
Embedded Files
Ryo Kinoshita
  • About me
  • Publications
  • Conference presentations
  • Other activities
Ryo Kinoshita
  • About me
  • Publications
  • Conference presentations
  • Other activities
  • More
    • About me
    • Publications
    • Conference presentations
    • Other activities

  1. 井上史也, 安齋麻美, 三浦郁修, 木下諒, 新井智, 神垣太郎, 鈴木基, 米岡大輔. 日本国内でのCOVID-19下水サーベイランスのエラー要因および継続的な実用性について. 日本公衆衛生雑誌. 2025. Accepted.

  2. Nakamura T, Kinoshita R, Endo A, Atkins KE, Oshitani H, Ibuka Y, Suzuki M, Ariyoshi K, O'Reilly KM. Continuing to be Cautious: Japanese Contact Patterns during the COVID-19 Pandemic and their Association with Public Health Recommendations. PLOS Glob Public Health. 2025 Sep 24;5(9):e0004600.

  3. Ith S, Kinoshita R, Miyamoto S, Tomo Y, Arashiro T, Arai S, Sakuraba S, Sugihara J, Wakita T, Suzuki T, Suzuki M, Yoneoka D. What drives respondents to seroepidemiological surveys? Insights from COVID-19 and implications for future pandemics.J Epidemiol. 2025 Aug 2.

  4. Kinoshita R*, Nishigaki A*, Sakuraba S, Sugihara J, Suzuki T, Suzuki M, Yoneoka D. Comparison of Infection-Induced SARS-CoV-2 Seroprevalence Across Large-Scale Residual Samples From Blood Donors, Commercial Laboratories, and Health Checkups in Japan, 2023. Open Forum Infect Dis. 2025 Jul 17;12(8):ofaf415. 

  5. Miyamoto S, Numakura K, Kinoshita R, Arashiro T, Takahashi H, Hibino H, Hayakawa M, Kanno T, Sataka A, Sakamoto R, Ainai A, Arai S, Suzuki M, Yoneoka D, Wakita T, Suzuki T. Serum anti-nucleocapsid antibody correlates of protection from SARS-CoV-2 re-infection regardless of symptoms or immune history. Commun Med (Lond). 2025 May 15;5(1):172.

  6. Kinoshita R, Miyamoto S, Suzuki T, Suzuki M, Yoneoka D. Interpreting the Influence of Using Blood Donor Residual Samples for SARS-CoV-2 Seroprevalence Studies in Japan: Cross-Sectional Survey Study. JMIR Public Health Surveill. 2025 Feb 10:11:e60467.

  7. Kinoshita R, Miyamoto S, Sakuraba S, Sugihara J, Suzuki M, Suzuki T, Yoneoka D. Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023. Emerg Infect Dis. 2024 Jun;30(6).

  8. Kinoshita R, Arai S, Suzuki M, Nishiura H. Identifying the Population Susceptible to Rubella in Japan, 2020: Fine-Scale Risk Mapping. Journal of Infection and Public Health. 2024. Mar 29;17(6):947-955. 

  9. Sassa M, Kinoshita R, Murano Y, Shoji H, Yoneoka D. Holiday effect on childbirth: A population-based analysis of 21,869,652 birth records, 1979-2018. PLoS One. 2024 Feb 14;19(2):e0296403.

  10. Kitamura N, Otani K, Kinoshita R, Yan F, Takizawa Y, Fukushima K, Yoneoka D, Suzuki M, Kamigaki T. Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant in Japan. The Lancet Regional Health-Western Pacific. 2023 Sep 25:41:100911.

  11. Kinoshita R, Arashiro T, Kitamura N, Arai S, Takahashi K, Suzuki T, Suzuki M, Yoneoka D. Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022. Emerg Infect Dis. 2023 Jul 28;29(9).

  12. Kinoshita R, Sassa M, Otake S, Yoshimatsu F, Shi S, Ueno R, Suzuki M, Yoneoka D. Impact of airline network on the global importation risk of mpox, 2022. Epidemiology & Infection. 2023;1-27. doi:10.1017/S0950268823000456

  13. Arashiro, T*, Arai, S*, Kinoshita R, Otani K, Miyamoto S, Yoneoka D, Kamigaki T, Takahashi H, Hibino H, Okuyama M, Hayashi A, Kikuchi F, Morino S, Takanashi S, Wakita T, Tanaka-Taya K, Suzuki T, Suzuki M. National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan. Influenza Other Respi Viruses. 2023; 17( 2):e13094. doi:10.1111/irv.13094

  14. Ko YK, Kinoshita R, Yamauchi M, Otani K, Kamigaki T, Kasuya K, Yoneoka D, Arima Y, Kobayashi Y, Arashiro T, Otsuka M, Shimbashi R, Suzuki M. Impact of the Coming-of-Age Day and ceremony on the risk of SARS-CoV-2 transmission in Japan: A natural-experimental study based on national surveillance data. Influenza Other Respir Viruses. 2022 Jul 27:10.1111/irv.13027. 

  15. Ko YK, Murayama H, Yamasaki L, Kinoshita R, Suzuki M, Nishiura H. Age-Dependent Effects of COVID-19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan. Emerg Infect Dis. 2022 Jul 12;28(9).

  16. Kinoshita R, Jung SM, Kobayashi T, Akhmetzhanov AR, Nishiura H. Epidemiology of coronavirus disease 2019 (COVID-19) in Japan during the first and second waves. Mathematical Biosciences and Engineering. 2022;19(6):6088-101. 

  17. Miyama T, Jung SM, Hayashi K, Anzai A, Kinoshita R, Kobayashi T, Linton NM, Suzuki A, Yang Y, Yuan B, Kayano T, Akhmetzhanov AR, Nishiura H. Phenomenological and mechanistic models for predicting early transmission data of COVID-19. Mathematical Biosciences and Engineering. 2022, 19.2: 2043-2055.

  18. Jung SM, Endo A, Kinoshita R , Nishiura H. Projecting a second wave of COVID-19 in Japan with variable interventions in high-risk settings. R. Soc. open sci. 2021.8202169202169

  19. 木下諒, 西浦博. 特集「COVID-19第2波に備えてできること」：新型コロナウイルスのクラスター解析と疫学. 臨床とウイルス（日本臨床ウイルス学会）.2020 Oct 48;4

  20. Kinoshita R, Anzai A, Jung SM, Linton NM, Miyama T, Kobayashi T, Hayashi K, Suzuki A, Yang Y, Akhmetzhanov AR, Nishiura H. Containment, contact tracing and asymptomatic transmission of novel coronavirus disease (COVID-19): A modelling study. J Clin Med. 2020. Sep 27;9(10) 

  21. Kayano T, Lee H, Kinoshita R, Nishiura H. Identifying geographic areas at risk of rubella epidemics in Japan using seroepidemiological data. Int J Infect Dis. 2020. Sep20;S1201-9712(20)32174-3 

  22. Hitoshi Oshitani, The Experts Members of The National COVID-19 Cluster Taskforce at Ministry of Health, Labour and Welfare, Japan. Cluster-based approach to Coronavirus Disease 2019 (COVID-19) response in Japan—February–April 2020, Japanese Journal of Infectious Diseases, JJID.2020.363

  23. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, Kinoshita R, Yang Y, Yuan B, Akhmetzhanov AR, Linton NM. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020 May; 94: 154–155.

  24. Kobayashi T, Jung SM, Linton NM, Kinoshita R, Hayashi K, Miyama T, Anzai A, Yang Y, Yuan B, Akhmetzhanov AR, Suzuki A, Nishiura H. Communicating the Risk of Death from Novel Coronavirus Disease (COVID-19). J Clin Med. 2020 Feb 21;9(2). pii: E580.

  25. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R, Nishiura H. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. J Clin Med. 2020 Feb 17;9(2). pii: E538.

  26. Jung SM, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, Kobayashi T, Kinoshita R, Nishiura H. Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases. J Clin Med. 2020 Feb 14;9(2). pii: E523.

  27. Nishiura H, Kobayashi T, Yang Y, Hayashi K, Miyama T, Kinoshita R, Linton NM, Jung SM, Yuan B, Suzuki A, Akhmetzhanov AR. The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights. J Clin Med. 2020 Feb 4;9(2). pii: E419.

  28. Anzai A, Kobayashi T, Linton NM, Kinoshita R, Hayashi K, Suzuki A, Yang Y, Jung SM, Miyama T, Akhmetzhanov AR, Nishiura H. Assessing the Impact of Reduced Travel on Exportation Dynamics of Novel Coronavirus Infection (COVID-19). J Clin Med. 2020 Feb 24;9(2). pii: E601.

  29. Kinoshita R*, Jung SM*, Thompson RN*, Linton NM, Yang Y, Akhmetzhanov AR, Nishiura H. Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019-2020. J Clin Med. 2020 Feb 27;9(3). pii: E637. 

  30. Nishiura H, Jung SM, Linton NM, Kinoshita R, Yang Y, Hayashi K, Kobayashi T, Yuan B, Akhmetzhanov AR. The Extent of Transmission of Novel Coronavirus in Wuhan, China, 2020. J Clin Med. 2020 Jan 24;9(2). https://doi.org/10.3390/jcm9020330

  31. Nishiura H, Kayano T, Kinoshita R. Overcoming the difficulty of achieving elimination goal for measles and rubella due to imported infections: Estimation of the reproduction number R for measles and rubella. Travel Med Infect Dis. 2019 Jul - Aug;30:137-138. https://doi.org/10.1016/j.tmaid.2019.05.004

  32. Ponce L, Kinoshita R, Nishiura H. Exploring human-animal interface of Ebola virus disease outbreaks. Mathematical Biosciences and Engineering. 2019, 16(4): 3130-3143, 2019. https://doi.org/10.3934/mbe.2019155

  33. Akhmetzhanov AR, Lee H, Jung SM, Kinoshita R, Shimizu K, Yoshii K, Nishiura H. Real time forecasting of measles using generation-dependent mathematical model in Japan, 2018. PLoS Curr. 2018 Oct 15;10. https://doi.org/10.1371/currents.outbreaks.3cc277d133e2d6078912800748dbb492

  34. Kinoshita R, Shimizu K, Nishiura H. Measles control in a measles-eliminated country, Japan. Travel Med Infect Dis. 2018 Sep-Oct;25:8-9. https://doi.org/10.1016/j.tmaid.2018.08.006 

  35. Shimizu K, Kinoshita R, Yoshii K, Akhmetzhanov AR, Jung SM, Lee H, Nishiura H. An investigation of a measles outbreak in Japan and Taiwan, China, March-May 2018. Western Pac Surveill Response J. 2018;9(3). https://doi.org/10.5365/wpsar.2018.9.2.005

  36. Saito MM, Ejima K, Kinoshita R, Nishiura H. Assessing the Effectiveness and Cost-Benefit of Test-and-Vaccinate Policy for Supplementary Vaccination against Rubella with Limited Doses. Int J Environ Res Public Health. 2018;15(4). https://doi.org/10.3390/ijerph15040572

  37. Kinoshita R, Nishiura H. Assessing age-dependent susceptibility to measles in Japan. Vaccine. 2017;35(25):3309-3317. https://doi.org/10.1016/j.vaccine.2017.05.011

  38. Nishiura H, Mizumoto K, Rock KS, Yasuda Y, Kinoshita R, Miyamatsu Y. A theoretical estimate of the risk of microcephaly during pregnancy with Zika virus infection. Epidemics. 2016; 15:66-70. http://dx.doi.org/10.1016/j.epidem.2016.03.001

  39. Nah K, Mizumoto K, Miyamatsu Y, Yasuda Y, Kinoshita R, Nishiura H. Estimating risks of importation and local transmission of Zika virus infection. PeerJ. 2016;4:e1904. http://dx.doi.org/10.7717/peerj.1904

  40. Nishiura H, Kinoshita R, Mizumoto K, Yasuda Y, Nah K. Transmission potential of Zika virus infection in the South Pacific. International Journal of Infectious Diseases. 2016;45:95-7. http://dx.doi.org/10.1016/j.ijid.2016.02.017

  41. Nomura S, Parsons AJQ, Hirabayashi M, Kinoshita R, Liao Y, Hodgson S. Social Determinants of Mid- to Long-term Disaster Impacts on Health: A Systematic Review. International Journal of Disaster Risk Reduction. 16 (2016): 53-67.  http://dx.doi.org/10.1016/j.ijdrr.2016.01.013 

  42. Nishiura H, Endo A, Saitoh M, Kinoshita R, Ueno R, Nakaoka S, Miyamatsu Y, Dong Y, Chowell G, Mizumoto K. Identifying determinants of heterogeneous transmission dynamics of the Middle East respiratory syndrome (MERS) outbreak in the Republic of Korea, 2015: a retrospective epidemiological analysis. BMJ Open. 2016;6(2):e009936. http://dx.doi.org/10.1136/bmjopen-2015-009936

  43. Kinoshita R, Nishiura H. Assessing herd immunity against rubella in Japan: a retrospective seroepidemiological analysis of age-dependent transmission dynamics. BMJ Open. 2016 Jan 27;6(1):e009928. http://dx.doi.org/10.1136/bmjopen-2015-009928

  44. Nishiura H, Kinoshita R, Miyamatsu Y, Mizumoto K. Investigating the immunizing effect of the rubella epidemic in Japan, 2012-14. International Journal of Infectious Diseases 2015;38:16-8. http://dx.doi.org/10.1016/j.ijid.2015.07.006

  45. 西浦博, 木下諒.特集「感染症の数理モデルと制御」：新興感染症の国際的伝播を予測する数理モデル.システム情報制御学会誌. 2015, 59(9), p. 446-451 (Link)

Google Sites
Report abuse
Google Sites
Report abuse